Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
Drugs
.
2016 Jul;76(10):1063-5.
doi: 10.1007/s40265-016-0594-z.
Authors
Working Group Nientemale DEI
;
R Vellucci
1
,
G Fanelli
2
,
P A Cortesi
3
,
R Pannuti
4
,
C Peruselli
5
,
P Romualdi
6
Affiliations
1
SOD Cure Palliative e Terapia del Dolore, Ospedale Universitario Careggi, Florence, Italy. renato.vellucci@gmail.com.
2
SC Anestesia, Rianimazione e Terapia Antalgica, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
3
Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
4
Fondazione ANT Italia Onlus, Andria, Italy.
5
SC Cure Palliative, Ospedale di Biella, Ponderano, BI, Italy.
6
Dipartimento di Farmacia e Biotecnologie, Alma mater studiorum, Università di Bologna, Bologna, Italy.
PMID:
27324270
PMCID:
PMC4920836
DOI:
10.1007/s40265-016-0594-z
No abstract available
Publication types
Letter
Comment
MeSH terms
Analgesics, Opioid / therapeutic use
Breakthrough Pain / diagnosis
Cancer Pain*
Expert Testimony*
Fentanyl / therapeutic use
Humans
Neoplasms / drug therapy
Substances
Analgesics, Opioid
Fentanyl